Ascentage Pharma Group International 6855.HK 價格預測與預測

Q: 技術分析指標如何適用於 6855.HK？

根據技術分析，Ascentage Pharma Group International 的綜合信號為 Sell。Ascentage Pharma Group International 有 2 個買入信號，0 個中性信號和 5 個賣出信號。

Q: 6855.HK 的費波那契回檔水準是多少？

Ascentage Pharma Group International 的費波那契回檔水準是 介於 23.6% 和 38.2% 之間。

Q: Ascentage Pharma Group International 的 RSI 是多少？

Ascentage Pharma Group International 的 RSI 目前為 28.51，表明處於 超賣 狀態

Q: Ascentage Pharma Group International 接下來 12 個月的價格是多少？

Ascentage Pharma Group International 6855.HK 接下來 12 個月的價格預估為 $101.66。

Q: Ascentage Pharma Group International 預計會漲到多高？

據華爾街分析師稱，Ascentage Pharma Group International 預計將達到 $119.7 的高預測值。

首頁

股票

6855.HK

預測

ASCENTAGE-B (6855.HK)

Ascentage Pharma Group International

HK$48.22

-1.51%

$-0.74

盤中： Jan 30, 15:41:41 HKT

關鍵數據

前收市價

$49.04

開盤價

$48.96

當日範圍

$47.6 - $50

52週區間

$31.35 - $95.35

交易量

1.7M

平均成交量

1.9M

每股盈餘 (TTM)

-4.01

股息收益率

市值

$17.9B

什麼是 ASCENTAGE-B？

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 605 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.

功能特性

交易策略

資源

市場

Utilizing our sophisticated predictive model, we anticipate notable price fluctuations for 6855.HK in the upcoming periods. Looking toward the future, our 2027 projection indicates an average price target of $101.66. The lowest target is $89.89 and the highest is $119.7. Empower your investment choices with our cutting-edge, data-driven analysis!

6855.HK 股價預測摘要

6855.HK 的頂級分析師評級

根據 13 位分析師對 6855.HK 的股票評級，更新於 Jan 01, 2026

Strong Buy

Strong buy

Buy

Hold

Sell

Strong sell

Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for 6855.HK. Our analysts highlight strong fundamentals and favorable market sentiment, positioning 6855.HK for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: 6855.HK is a Strong Buy candidate.

6855.HK stock price ended at $48.4 on 星期五, after dropping 1.31%

On the latest trading day Jan 30, 2026, the stock price of 6855.HK fell by 1.31%, dropping from $48.96 to $48.40. During the session, the stock saw a volatility of 3.65%, with prices oscillating between a daily low of $48.24 and a high of $50.00. On the latest trading day, the trading volume for 6855.HK decreased by 469.5K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 796.2K shares were traded, with a market value of approximately $17.9B.

6855.HK 技術面訊號

技術面訊號摘要

購買訊號 2

中性訊號 0

賣出訊號 5

Strong Sell

Sell

Neutral

Buy

Strong Buy

6855.HK 目前顯示 2 個買入訊號與 5 個賣出訊號。該股票自 12:00 AM 以來一直處於下跌趨勢狀態，在此期間價格總共變動了 -2.1%。整體而言，技術指標顯示中期後市趨勢為 Sell。

6855.HK 的看漲／看跌訊號

我們的演算法透過分析移動平均線、RSI、MACD 和成交量等關鍵指標，為6855.HK生成看漲和看跌訊號。這些見解可助您做出明智的投資決策。

後續問題

技術分析指標如何適用於 6855.HK？



6855.HK 的費波那契回檔水準是多少？



Ascentage Pharma Group International 的 RSI 是多少？



Ascentage Pharma Group International 接下來 12 個月的價格是多少？



Ascentage Pharma Group International 預計會漲到多高？



Ascentage Pharma Group International（6855.HK）價格

6855.HK 股價走勢圖